LILRB2 and relapsing-remitting multiple sclerosis: CD14+ monocytes derived from treatment-naïve patients with RRMS (n = 24) or CIS (n = 6) and healthy controls (n = 14) were analyzed for surface expression of ILT3 and ILT4 by flow cytometry.